JP2023508011A5 - - Google Patents

Info

Publication number
JP2023508011A5
JP2023508011A5 JP2022537669A JP2022537669A JP2023508011A5 JP 2023508011 A5 JP2023508011 A5 JP 2023508011A5 JP 2022537669 A JP2022537669 A JP 2022537669A JP 2022537669 A JP2022537669 A JP 2022537669A JP 2023508011 A5 JP2023508011 A5 JP 2023508011A5
Authority
JP
Japan
Prior art keywords
lemborexant
child
pharmaceutically acceptable
acceptable salt
dosage form
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022537669A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023508011A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/065891 external-priority patent/WO2021127359A1/en
Publication of JP2023508011A publication Critical patent/JP2023508011A/ja
Publication of JP2023508011A5 publication Critical patent/JP2023508011A5/ja
Priority to JP2025131238A priority Critical patent/JP2025160480A/ja
Pending legal-status Critical Current

Links

JP2022537669A 2019-12-20 2020-12-18 不眠症を治療するためのレンボレキサントの使用 Pending JP2023508011A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025131238A JP2025160480A (ja) 2019-12-20 2025-08-06 不眠症を治療するためのレンボレキサントの使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962951638P 2019-12-20 2019-12-20
US62/951,638 2019-12-20
PCT/US2020/065891 WO2021127359A1 (en) 2019-12-20 2020-12-18 Use of lemborexant for treating insomnia

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025131238A Division JP2025160480A (ja) 2019-12-20 2025-08-06 不眠症を治療するためのレンボレキサントの使用

Publications (2)

Publication Number Publication Date
JP2023508011A JP2023508011A (ja) 2023-02-28
JP2023508011A5 true JP2023508011A5 (cg-RX-API-DMAC7.html) 2023-12-22

Family

ID=74191874

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022537669A Pending JP2023508011A (ja) 2019-12-20 2020-12-18 不眠症を治療するためのレンボレキサントの使用
JP2025131238A Pending JP2025160480A (ja) 2019-12-20 2025-08-06 不眠症を治療するためのレンボレキサントの使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025131238A Pending JP2025160480A (ja) 2019-12-20 2025-08-06 不眠症を治療するためのレンボレキサントの使用

Country Status (11)

Country Link
US (1) US20230051268A1 (cg-RX-API-DMAC7.html)
EP (1) EP4076463A1 (cg-RX-API-DMAC7.html)
JP (2) JP2023508011A (cg-RX-API-DMAC7.html)
KR (1) KR20220119065A (cg-RX-API-DMAC7.html)
CN (1) CN115003305A (cg-RX-API-DMAC7.html)
AU (1) AU2020408557A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022012246A2 (cg-RX-API-DMAC7.html)
CA (1) CA3165481A1 (cg-RX-API-DMAC7.html)
MX (1) MX2022007304A (cg-RX-API-DMAC7.html)
TW (1) TW202137986A (cg-RX-API-DMAC7.html)
WO (1) WO2021127359A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20260029363A (ko) * 2023-06-29 2026-03-04 얀센 파마슈티카 엔브이 셀토렉산트를 이용한 우울증 치료 방법

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0828751A4 (en) 1995-05-05 1999-01-20 Human Genome Sciences Inc HUMAN NEUROPEPTIDE RECEPTOR
US6309854B1 (en) 1996-12-17 2001-10-30 Smithkline Beecham Corporation Polynucleotides encoding ligands of the neuropeptide receptor HFGAN72
US5935814A (en) 1997-04-30 1999-08-10 Smithkline Beecham Corporation Polynucleotides encoding HFGAN72Y receptor
US6020157A (en) 1997-04-30 2000-02-01 Smithkline Beecham Corporation Polynucleotides encoding HFGAN72X receptor
US6166193A (en) 1997-07-25 2000-12-26 Board Of Regents, University Of Texas System Polynucleotides encoding MY1 receptor
RU2571414C2 (ru) 2010-09-22 2015-12-20 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Циклопропановые соединения
US9416109B2 (en) 2012-02-17 2016-08-16 Eisai R&D Management Co., Ltd. Methods and compounds useful in the synthesis of orexin-2 receptor antagonists
JP6659681B2 (ja) * 2014-10-23 2020-03-04 エーザイ・アール・アンド・ディー・マネジメント株式会社 不眠症を治療するための組成物および方法
KR20230170136A (ko) * 2017-01-27 2023-12-18 뉴로크린 바이오사이언시즈 인코퍼레이티드 특정 vmat2 억제제의 투여 방법

Similar Documents

Publication Publication Date Title
RU2404750C2 (ru) Композиция, содержащая основу или покрытие для замедленного высвобождения и антагонист nmda рецептора, способ введения такого nmda антагониста субъекту
JP6196041B2 (ja) 大うつ病を有する患者において減量療法を提供する方法
JP2021120379A5 (cg-RX-API-DMAC7.html)
US11744808B2 (en) Compositions and methods for treating non-alcoholic steatohepatitis
FI3518933T4 (fi) Menetelmiä kohtumyooman ja endometrioosin hoitamiseksi
JP2007512371A5 (cg-RX-API-DMAC7.html)
RU2008150622A (ru) Лечение агонистом мелатонина
MXPA05012810A (es) Formas de dosis oral de memantina.
AR045289A1 (es) Forma de dosificacion oral de liberacion controlada que comprende 4-(2-di-n-propilaminoetil) - 2(3h)-indolona (ropi-nirol) y uso de dicha forma de dosificacion para la elaboracion de un medicamento
JPH0635382B2 (ja) 抗不安薬としてのフルオキセチンの使用法
JP2020500864A5 (cg-RX-API-DMAC7.html)
RU2008119454A (ru) Лекарственное средство для защиты моторного нейрона у пациентов с боковым амиотрофическим склерозом
JP2003519181A (ja) 抗高血圧剤に対する抵抗性及び関連状態を処置する方法及び処方物
RU2008102911A (ru) Фармацевтические составы на основе гуанфацина, подходящие для ежедневного введения в виде единичной дозированной формы
JPWO2008090736A1 (ja) アルツハイマー型認知症の予防及び治療のための医薬
JP2023549849A5 (cg-RX-API-DMAC7.html)
Bae et al. Stevens-johnson syndrome induced by carbamazepine treatment in a patient who previously had carbamazepine induced pruritus-a case report
Rabben et al. Interindividual differences in the analgesic response to ketamine in chronic orofacial pain
IL272834B1 (en) Compositions of amantadine, their preparation, and methods of use
JP2015521647A5 (cg-RX-API-DMAC7.html)
IE851848L (en) Propiophenone compound against sexual dysfunction
US20180289708A1 (en) Low dose oral dipyridamole compositions and uses thereof
McHutchison et al. 745 Efficacy and safety of eltrombopag, an oral platelet growth factor, in subjects with HCV associated thrombocytopenia: Preliminary results from a phase II dose-ranging study
JPH10506097A (ja) Jet lagを緩和するための方法と医薬
JP4384435B2 (ja) くしゃみ抑制組成物